These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 22974133)

  • 1. Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.
    Zaman M; Abdel-Aal AB; Fujita Y; Ziora ZM; Batzloff MR; Good MF; Toth I
    J Med Chem; 2012 Oct; 55(19):8515-23. PubMed ID: 22974133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization.
    Batzloff MR; Hartas J; Zeng W; Jackson DC; Good MF
    J Infect Dis; 2006 Aug; 194(3):325-30. PubMed ID: 16826480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
    J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components.
    Abdel-Aal AB; Zaman M; Fujita Y; Batzloff MR; Good MF; Toth I
    J Med Chem; 2010 Nov; 53(22):8041-6. PubMed ID: 21028828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus.
    Batzloff MR; Yan H; Davies MR; Hartas J; Lowell GH; White G; Burt DS; Leanderson T; Good MF
    J Infect Dis; 2005 Oct; 192(8):1450-5. PubMed ID: 16170764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates.
    Abdel-Aal AB; Batzloff MR; Fujita Y; Barozzi N; Faria A; Simerska P; Moyle PM; Good MF; Toth I
    J Med Chem; 2008 Jan; 51(1):167-72. PubMed ID: 18072728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
    Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
    J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
    Olive C; Hsien K; Horváth A; Clair T; Yarwood P; Toth I; Good MF
    Vaccine; 2005 Mar; 23(17-18):2298-303. PubMed ID: 15755615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a liposaccharide-based delivery system and its application to the design of group A streptococcal vaccines.
    Simerska P; Abdel-Aal AB; Fujita Y; Moyle PM; McGeary RP; Batzloff MR; Olive C; Good MF; Toth I
    J Med Chem; 2008 Mar; 51(5):1447-52. PubMed ID: 18278857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope.
    Olive C; Clair T; Yarwood P; Good MF
    Vaccine; 2002 Jun; 20(21-22):2816-25. PubMed ID: 12034109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bactericidal activity of M protein conserved region antibodies against group A streptococcal isolates from the Northern Thai population.
    Yoonim N; Olive C; Pruksachatkunakorn C; Pruksakorn S
    BMC Microbiol; 2006 Aug; 6():71. PubMed ID: 16895610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation.
    Moyle PM; Olive C; Ho MF; Good MF; Toth I
    J Med Chem; 2006 Oct; 49(21):6364-70. PubMed ID: 17034142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid core peptide technology and group A streptococcal vaccine delivery.
    Olive C; Batzloff MR; Toth I
    Expert Rev Vaccines; 2004 Feb; 3(1):43-58. PubMed ID: 14761243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationship.
    Zaman M; Abdel-Aal AB; Fujita Y; Phillipps KS; Batzloff MR; Good MF; Toth I
    PLoS One; 2012; 7(1):e30146. PubMed ID: 22253911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage.
    Horváth A; Olive C; Karpati L; Sun HK; Good M; Toth I
    J Med Chem; 2004 Jul; 47(16):4100-4. PubMed ID: 15267249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
    Olive C; Schulze K; Sun HK; Ebensen T; Horváth A; Toth I; Guzman CA
    Vaccine; 2007 Feb; 25(10):1789-97. PubMed ID: 17229503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural optimisation of a conformational epitope improves antigenicity when expressed as a recombinant fusion protein.
    Georgousakis MM; Hofmann A; Batzloff MR; McMillan DJ; Sriprakash KS
    Vaccine; 2009 Nov; 27(48):6799-806. PubMed ID: 19729086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in silico analysis of two vaccine candidates for group A streptococcus predicts that they both may have similar safety profiles.
    Shaila MS; Nayak R; Prakash SS; Georgousakis M; Brandt E; McMillan DJ; Batzloff MR; Pruksakorn S; Good MF; Sriprakash KS
    Vaccine; 2007 May; 25(18):3567-73. PubMed ID: 17293014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
    Mannam P; Jones KF; Geller BL
    Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of conformational mimetics of conserved Streptococcus pyogenes minimal epitope as vaccine candidates.
    Zhong W; Skwarczynski M; Toth I
    Curr Drug Deliv; 2009 Oct; 6(5):520-7. PubMed ID: 19863488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.